| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
|
Clin Cancer Res
|
2005
|
5.70
|
|
2
|
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.
|
Gut
|
2013
|
2.86
|
|
3
|
Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
|
Hum Mutat
|
2010
|
2.75
|
|
4
|
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
|
Nature
|
2012
|
2.66
|
|
5
|
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
|
Hum Mol Genet
|
2009
|
2.13
|
|
6
|
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
|
Cancer Res
|
2010
|
1.90
|
|
7
|
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
|
Int J Cancer
|
2007
|
1.84
|
|
8
|
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
|
BMC Cancer
|
2008
|
1.61
|
|
9
|
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
|
PLoS Genet
|
2010
|
1.56
|
|
10
|
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
|
Hum Mol Genet
|
2011
|
1.51
|
|
11
|
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
|
Breast Cancer Res
|
2012
|
1.38
|
|
12
|
Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor.
|
Hum Mol Genet
|
2007
|
1.36
|
|
13
|
Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.36
|
|
14
|
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
|
Clin Cancer Res
|
2008
|
1.28
|
|
15
|
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
|
Int J Cancer
|
2002
|
1.26
|
|
16
|
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
|
Breast Cancer Res
|
2011
|
1.22
|
|
17
|
Life expectancy in hereditary cancer predisposing diseases: an observational study.
|
J Med Genet
|
2012
|
1.20
|
|
18
|
Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.
|
Clin Endocrinol (Oxf)
|
2003
|
1.14
|
|
19
|
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.
|
PLoS Biol
|
2011
|
1.12
|
|
20
|
Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
|
Breast Cancer Res Treat
|
2013
|
1.09
|
|
21
|
Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res
|
2006
|
1.03
|
|
22
|
BRCA1/2 predictive testing: a study of uptake in two centres.
|
Eur J Hum Genet
|
2004
|
1.02
|
|
23
|
A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma.
|
J Clin Endocrinol Metab
|
2013
|
1.02
|
|
24
|
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
|
Hum Mutat
|
2012
|
0.98
|
|
25
|
Gene-gene interactions in breast cancer susceptibility.
|
Hum Mol Genet
|
2011
|
0.97
|
|
26
|
Do women understand the odds? Risk perceptions and recall of risk information in women with a family history of breast cancer.
|
Community Genet
|
2003
|
0.92
|
|
27
|
Breast cancer susceptibility variants alter risks in familial disease.
|
J Med Genet
|
2009
|
0.90
|
|
28
|
BRCA1/2 mutation analysis in male breast cancer families from North West England.
|
Fam Cancer
|
2007
|
0.90
|
|
29
|
Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.
|
Eur J Hum Genet
|
2009
|
0.89
|
|
30
|
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.89
|
|
31
|
Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma.
|
Clin Endocrinol (Oxf)
|
2013
|
0.89
|
|
32
|
A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer.
|
Int J Cancer
|
2013
|
0.88
|
|
33
|
Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
|
Breast Cancer Res Treat
|
2013
|
0.87
|
|
34
|
Is it time to abandon microsatellite instability as a pre-screen for selecting families for mutation testing for mismatch repair genes?
|
J Clin Oncol
|
2006
|
0.86
|
|
35
|
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
|
Breast Cancer Res Treat
|
2008
|
0.84
|
|
36
|
BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.
|
J Med Genet
|
2010
|
0.83
|
|
37
|
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.83
|
|
38
|
High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?
|
Breast Cancer Res Treat
|
2012
|
0.82
|
|
39
|
Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.82
|
|
40
|
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.
|
Breast Cancer Res
|
2010
|
0.82
|
|
41
|
Familial colorectal cancer referral to regional genetics department--a single centre experience.
|
Fam Cancer
|
2007
|
0.82
|
|
42
|
Development of a scoring system to screen for BRCA1/2 mutations.
|
Methods Mol Biol
|
2010
|
0.81
|
|
43
|
Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.81
|
|
44
|
Update on genetic predisposition to breast cancer.
|
Expert Rev Anticancer Ther
|
2009
|
0.80
|
|
45
|
Exploring the link between MORF4L1 and risk of breast cancer.
|
Breast Cancer Res
|
2011
|
0.79
|
|
46
|
Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?
|
BMC Med Inform Decis Mak
|
2014
|
0.77
|
|
47
|
Re: risk-reduction mastectomy: clinical issues and research needs.
|
J Natl Cancer Inst
|
2002
|
0.75
|
|
48
|
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
|
J Natl Cancer Inst
|
2017
|
0.75
|
|
49
|
Optimal selection of individuals for BRCA mutation testing.
|
J Clin Oncol
|
2006
|
0.75
|